All Three Athos Co-Founders Named to Stanford’s List of the World’s Top 2% of Scientists
LOS ANGELES, CA / ACCESSWIRE / October 12, 2023 / Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with immune-mediated diseases and cancer, announced today that each one of the three co-founders of Athos has been named to Stanford University’s prestigious “Top 2%” […]
Athos Student Internship Program
The internship program was designed to expose students to Athos’s unique, innovative, and diverse interdisciplinary approach to science and drug development, and to create a bridge for students between academia and the professional world. We provide invaluable and practical experiences such as how to pipette and use scientific equipment, how to create different concentrations of […]
Tony Zingale, Noted Chief Executive Officer and Entrepreneur, Appointed as an Observer to the Board of Directors of Athos Therapeutics
LOS ANGELES, May 17, 2023 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics for patients with immune-mediated diseases and cancer, announced today that Tony Zingale, a veteran software executive, was appointed as an observer to the Board of Directors of Athos Therapeutics. “Athos […]
Athos Therapeutics Announces Dosing of the First Patient in the First-In-Human Phase 1 Clinical Trial of ATH-063
ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn’s disease – 27 April 2023, 11:30 am ET LOS ANGELES, April 27, 2023 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule therapeutics […]
Athos Therapeutics Announces Research Collaboration with the University of Ioannina to Advance the Field of Inflammatory Bowel Disease
Athos to perform molecular and computational analyses of patient biomaterials from de-identified Inflammatory Bowel Disease patient samples from the Faculty of Medicine, School of Health Sciences and the Division of Gastroenterology at the University Hospital of Ioannina based in Ioannina, Greece. 19 April, 11:00 am ET LOS ANGELES, April 19, 2023 — Athos Therapeutics, Inc. (“Athos”), […]
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063
ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn’s disease – 29 March 2023, 11:30 am ET LOS ANGELES, March 29, 2023 — Athos Therapeutics, Inc. (“Athos”), a clinical stage biotechnology company pioneering the development of artificial intelligence-based precision small molecule […]
Athos Therapeutics Announces Proteomics Research Collaboration for Inflammatory Bowel Disease with Caltech
Athos will use specialized facilities and equipment at Caltech to perform molecular analysis and spectrometry-based proteomics on primary human single cells, blood, and tissue biopsies from de-identified Inflammatory Bowel Disease (IBD) patient samples. Thursday August 25, 11:00 am ET LOS ANGELES, August 25, 2022 — Athos Therapeutics, Inc. (“Athos”) is a late-stage preclinical biotech company […]
Athos Therapeutics Announces Research Collaboration to Advance Precision Medicine in Inflammatory Bowel Disease
Athos to perform molecular analysis of biopsies from de-identified Inflammatory Bowel Disease patient samples from Lahey Hospital & Medical Center based in Burlington, Massachusetts. Monday July 11, 11:00 am ET LOS ANGELES, July 11, 2022 — Athos Therapeutics, Inc. (“Athos”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases […]
Abraham Verghese MD, Noted Stanford Physician and Recipient of the National Humanities Medal at the White House from former President Obama, Appointed to the Board of Directors of Athos Therapeutics
LOS ANGELES, May 18, 2022 — Athos Therapeutics, Inc. (the “Company”), a late-stage preclinical biotech company using artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced today that Abraham Verghese, MD, MACP has been named to the Company’s Board of Directors. “I am honored to join the Athos Board of Directors,” […]
Athos Therapeutics Announces the Completion of its Oversubscribed Series A Financing
